We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

By LabMedica International staff writers
Posted on 04 Nov 2014
Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia.

An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to standard chemotherapy drugs that target cancer cells. More...


In a report on the research with mice and human laboratory cells, which was published in the October 23, 2014, edition of the journal Nature, investigators from New York University (NYU) Langone Medical Center (New York, NY, USA) concluded that the enzyme JMJD3 acts as a cancer “on” switch by splitting off a methyl group of another protein that is usually methylated by a tumor-suppressing enzyme. This enzyme, known as polycomb repressive complex 2 (PRC2), acts, in turn, to inactivate cancer cell proliferation.

The destabilizing and getting rid of PRC2, as the same researchers previously revealed, leads to the activation of the NOTCH1 biologic pathway, a process common to many cancers but particularly active in at least 50% of all individuals with T-cell acute lymphoblastic leukemia.

“Our investigations are showing incredible promise in fighting this disease at the transcriptional level,” says senior study investigator and NYU Langone cancer biologist Iannis Aifantis, PhD. “We are blocking the action of enzymes controlling the transcription of proteins involved in leukemia rather than attempting to directly suppress cancer genes.”

The researchers noted that the drug manufacturer, GlaxoSmithKline (Middlesex, UK), is already developing an investigational compound called GSKJ4, whose treatment path follows the biologic blue print revealed in the new research. If GSKJ4 works in further testing to prevent JMJD3 from destabilizing and expelling PRC2, Dr. Aifantis noted, it could become the first of its kind option to standard chemotherapy in years for treating this type of leukemia.

“Revealing the actions of JMJD3, and successfully blocking the enzyme to stall tumor progression, shows that new treatments for T-cell acute lymphoblastic leukemia are not simply theoretical, but practical,” added Dr. Aifantis, chair of the department of pathology at NYU Langone.

Dr. Aifantis reported that the latest findings are the culmination of several years of research by his team to unravel precisely how PRC2 inhibits tumor growth since the investigators first reported the phenomenon in leukemia published in 2012 in the journal Nature Medicine. For this study, the researchers investigated exactly how demethylation, the removal of a methyl chemical bond-triggers the chain of events that evicts PRC2 from cells, thereby removing PRC2 suppression of NOTCH1, which directly binds to and activates cancer-causing genes.

Specifically, the researchers focused on a protein controlled and methylated by PRC2 called histone 3 lysine 27 (H3K27) as well as two other enzymes closely tied to H3K27: JMJD3 and UTX, the latter short for ubiquitously transcribed tetratricopeptide repeat X-linked protein.

What the study found is that JMJD3 was highly active in both mice and human leukemia cells at all stages of tumor growth and development. By contrast, UTX was not overly produced in leukemia, but highly active in noncancerous mouse and human cells. When mice and human leukemia cells were treated with the experimental drug GSKJ4, JMJD3 activity blocked and all cancer cells ultimately died, the researchers reported.

Subsequent genetic research showed that in leukemic mice bred so that they are unable to make JMJD3, NOTCH1 activity dropped, while UTX activity remained the same. The disease also progressed much faster, the investigators discovered, in mice bred without UTX, while mice lived longer if they produced UTX. The findings suggest that UTX production controls several tumor-suppressing genes.

To additionally validate the findings, researchers screened more than 200 blood samples from children and adults with T-cell acute lymphoblastic leukemia, revealing several common mutations in UTX. Plans are ongoing, according to Dr. Aifantis, to assess GSKJ4 against human leukemia cells transplanted into mice. Other research will use the drug molecule in combination with standard chemotherapy in animal models with leukemia.

“Our report serves as a valuable reminder of just how complex cancers like T-cell acute lymphoblastic leukemia can be, and that enzymes can play many, even opposing, roles in both tumor growth and suppression,” concluded Dr. Aifantis.

Related Links:

New York University Langone Medical Center
GlaxoSmithKline



Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Portable Electronic Pipette
Mini 96
New
Blood Glucose Test Strip
AutoSense Test
New
Gold Member
Automatic Hematology Analyzer
DH-800 Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Over 100 new epigenetic biomarkers may help predict cardiovascular disease risk (Photo courtesy of 123RF)

Routine Blood Draws Could Detect Epigenetic Biomarkers for Predicting Cardiovascular Disease Risk

Cardiovascular disease is a leading cause of death worldwide, yet predicting individual risk remains a persistent challenge. Traditional risk factors, while useful, do not fully capture biological changes... Read more

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The VENTANA HER2 (4B5) test is now CE-IVDR approved (Photo courtesy of Roche)

Companion Diagnostic Test Identifies HER2-Ultralow Breast Cancer and Biliary Tract Cancer Patients

Breast cancer is the most common cancer in Europe, with more than 564,000 new cases and 145,000 deaths annually. Metastatic breast cancer is rising in younger populations and remains the leading cause... Read more

Pathology

view channel
Image: An adult fibrosarcoma case report has shown the importance of early diagnosis and targeted therapy (Photo courtesy of Sultana and Sailaja/Oncoscience)

Accurate Pathological Analysis Improves Treatment Outcomes for Adult Fibrosarcoma

Adult fibrosarcoma is a rare and highly aggressive malignancy that develops in connective tissue and often affects the limbs, trunk, or head and neck region. Diagnosis is complex because tumors can mimic... Read more

Technology

view channel
Image: Conceptual design of the CORAL capsule for microbial sampling in the small intestine (H. Mohammed et al., Device (2025). DOI: 10.1016/j.device.2025.100904)

Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine

The gut microbiome has been linked to conditions ranging from immune disorders to mental health, yet conventional stool tests often fail to capture bacterial populations in the small intestine.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.